CXCR4 and RANK Combination as a Predictor of Breast Cancer Bone Metastasis in Indonesia

Erwin D Yulian1*, Sonar S Panigoro1, Bajuadji Sudijono2, Walta Gautama3, Primariadewi Rustamadji4 and Ricky Dosan1

1Surgical Oncology Division, Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, University of Indonesia, Indonesia
2Surgical Oncology Division, Department of Surgery, Koja District Hospital, Indonesia
3Surgical Oncology Division, Department of Surgery, Dharmais Cancer Hospital, Indonesia
4Department of Anatomical Pathology, Faculty of Medicine, University of Indonesia, Indonesia

Received: 09 January, 2021
Accepted: 08 February, 2021
Published: 10 February, 2021

*Corresponding authors: Erwin D Yulian, MD, PhD, Surgical Oncology Division, Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, University of Indonesia, Indonesia, Tel: +6281315249627; E-mail: erwin.yulian@uio.ac.id

Keywords: Breast cancer; CXC chemokine receptor 4; Receptor activator of nuclear factor-kappa B; Bone; Metastasis

Abstract

Background: Breast cancer has the highest prevalence and incidence among cancers in women. Moreover, it is the most prevalent among all other cancers in Indonesia. Bone metastasis results in higher incidence, better overall survival, but requires higher-cost treatments than visceral metastasis. Therefore, an early predictor of bone metastasis is needed to make early interventions to be efficiently given. Instead of other biomarkers of bone metastasis, CXCR4 and RANK are highly expressed in breast cancer and correlate with bone metastasis. Hence this study is expected to prove the potential of CXCR4 and RANK combination as a predictor of breast cancer bone metastasis.

Methods: In a case-control study, CXCR4 and RANK immunohistochemistry tests were done in 58 stage I-IV breast cancer Indonesian subjects. Association between marker combinations and incidence of bone metastasis was analyzed. Then, the diagnosis accuracy values were calculated. Moreover, its associations with clinicopathological factors were also examined.

Results: There was a significant association of the highly expressed CXCR4 and RANK combination with bone metastasis (P<0.01). Besides, the combination of CXCR4 and RANK detections resulted in 100% sensitivity and 66% specificity in predicting bone metastasis. Breast cancer's stage was significantly associated with CXCR4 and RANK expressions combination (P<0.01).

Conclusions: A combination of CXCR4 and RANK expressions could act as a screening method to predict the bone metastasis in breast cancer.

Abbreviations

IL-8: Interleukin-8; RANK: Receptor Activator of Nuclear Factor Kappa-B; RANKL: Receptor Activator of Nuclear Factor Kappa-B Ligand; CXCR4: C-X-C Chemokine Receptor Type 4; PTHrP: Parathyroid Hormone-related Protein; B-CTX : Beta-C-Terminal Telopeptide; BM: Bone Metastasis; NBM: Non-Bone Metastasis; IHC: Immunohistochemical; CSLEX-1: Sialyl Lewis X-1 (CSLEX-1) with Cancer Antigen 15-3 (CA 15-3); CA 15-3: Cancer Antigen 15-3; NTx: N-Telopeptide of type I collagen

Introduction

Breast cancer has the highest prevalence and incidence among any other cancers in women [1]. In Indonesia, breast cancer is the most prevalent among all cancer [1,2]. Based on Global Burden of Cancer 2018, the global incidence of breast cancer was around 2,093,876 and the mortality was around 1,761,007. In Indonesia, the incidence was estimated at around 58,256 and the mortality was around 22,692 [1].

Breast cancer frequently metastasizes to bone approximately in 70% of advanced breast cancer patients [3].
Even though bone metastasis results in a better overall survival rather than visceral metastasis, it gives an enormous burden to the treatment cost. Hence, tumor markers are expected to early predict the bone metastasis [3–5]. This may help early intervention to enhance the quality of life and reduce the treatment cost of the patient.

Many biomarkers were hypothesized to be implicated in breast cancer bone metastasis such as Osteopontin, Osteonectin, Interleukin-8 (IL-8), Receptor Activator of Nuclear Factor Kappa-B (RANK), Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), C-X-C Chemokine Receptor Type 4 (CXCR4), bone sialoprotein, tumor cell surface’s integrin, Fas/Fas ligand, Parathyroid Hormone-related Protein (PTHrP), and Beta-C-Terminal Telopeptide (B-CtX) [6–9]. Among those markers, CXCR4 and RANK are known to have the greatest association with breast cancer bone metastasis, and both are involved in cancer cell’s homing to bones [10]. Moreover, CXCR4 and RANK act in the earliest cascade of the bone metastasis process [11]. Hence, this study aims to prove the potential of combined CXCR4 and RANK detections in predicting the bone metastasis occurrence of a breast cancer patient.

Methods

A retrospective case–control study was conducted in a national general hospital. This study had been approved by medical ethics committee of the university. Fifty-eight breast cancer specimens were obtained from an Anatomical Pathology Laboratory between January 2015 to October 2016. Moreover, the consecutive sampling method was used. Paraffin-embedded tissue blocks from stage I–IV breast cancer subjects were divided into two groups based on the presence of bone metastasis (which were confirmed by radiological examinations) within 5 years after initial breast cancer diagnosis (based on data stated in medical record): Bone Metastasis (BM) vs Non–Bone Metastasis (NBM). Paraffin blocks that were damaged in the process or taken from patients with any previous treatment were excluded.

The paraffin-embedded tissue blocks were cut into four µm sections, one tissue section was then stained with Hematoxylin and Eosin to confirm the breast cancer. Two other tissue sections were used for CXCR4 and RANK immunohistochemistry staining. Immunohistochemistry staining was done using an automatic immunohistochemical stainer. Ventana Roche BenchMark XT. CXCR4 GTX22090 (1:100 dilution) and RANK GTX31188 (1:200 dilution) were used as the immunohistochemical markers. Antigen–antibody reactions were visualized by Ultraview Brown Counterstain DAB Detection Kit (Ventana Medical Systems).

All Immunohistochemical (IHC) stains were then examined and scored by experienced breast pathologists. Cells from five random different fields were counted using high magnification.

Positive and negative control specimens for each marker analysis were used in this study for the comparison. Positive controls were breast cancer specimen samples showing both positive marker expressions. Besides, negative controls were specimens prepared through the same procedure but without using the primary antibody.

The following IHC staining scoring is taken and modified from the previous method used in a study by Sun, et al. [12]. The percentage of CXCR4 positive tumor was determined semi-quantitatively as follows: 0 (0%), 1 (1–10% positive cells), 2 (11–50% positive cells), 3 (51–80% positive cells), and 4 (81–100% positive cells). Cytoplasmic staining intensity was classified into 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Then, the positive cell percentage and staining intensity were multiplied to define a composite score. Composite score was classified into 0 (negative), + (1–4), ++ (5–8), and +++ (9–12). CXCR4 was considered highly expressed if the composite score was ++ or +++ (5–12 score). The intensity of RANK staining was classified into four groups based on a method by Li, et al. including absent (0), positive but less intense (1), same intense (2), and more intense (3) compared to the positive control [13]. A more than 1 staining intensity score in more than 50% of cancer cells was considered as highly expressed. The combination of CXCR4 and RANK expressions was considered high if one or both of the markers were highly expressed.

Besides, the associations of marker expressions with metastasis, menopausal status, cancer stadium, lymph node involvement, hormonal receptor, and HER–2 amplification were also analyzed.

Shapiro–Wilk test was used for normality test, if P<0.05 the data distribution was normal and the data would be presented as mean±deviation standard. Otherwise, the data distribution was considered not normal and the data would be presented as median (minimum–maximum). Chi–Square/Fisher–Exact was used for analytical test for comparing BM and NBM group depended on the normality test.

Results

A total of 58 women breast cancer subjects participated in this study. Each of BM and NBM group included 29 subjects. In BM group, 51.7% had menopause, 100% had late-stage breast cancer, 100% had high tumor grade, 65.5% had No Special Type (NST), 72.4% had lymph node involvement, 86.2% were Estrogen Receptor/ Progesterone Receptor (ER/PR) positive, and 62.1% had HER–2 amplification. In NBM Group, 51.7% had menopause, 27.6% had late-stage breast cancer, 93.1% had high tumor grade, 58.6% had NST type, 44.8% had lymph node involvement, 82.6% were ER/PR positive, and 48.3% had HER–2 amplification. The detailed data on the characteristics of subjects are provided in Table 1. The majority of subjects with bone metastasis had highly–expressed CXCR4 and RANK. In contrast, most of the non–bone metastasis subjects showed low expression of both markers. The representative images of immunohistochemistry results are provided in Figures 1, 2.
would have 134.4 folds of risk for bone metastasis than low CXCR4 expressions. Meanwhile, breast cancer subjects with high–RANK expressions would have 88 folds of risk for bone metastasis than low–RANK expressions. The results of the analysis of the associations can be seen in Table 2. The authors assessed the diagnostic accuracy of CXCR4, RANK, and CXCR4+RANK expression in breast cancer bone metastasis based on sensitivity, specificity, positive predictive value, and negative predictive value. The results of the calculation on diagnosis accuracy are provided in Table 3. The sensitivity and negative predictive value of the CXCR4+RANK combination was 100% and higher than the values got from the single marker usage. However, the specificity and the positive predictive values of the marker combination were lower than the single marker usage.

**Association of clinicopathological features with CXCR4 expression, RANK expression and bone metastasis**

The relationship between clinicopathological features and breast cancer bone metastasis was assessed. By using bivariate analysis as shown in Table 4, the authors found a significant relationship between breast cancer staging \( (P < 0.01) \), lymph node involvement \( (P = 0.03) \), CXCR4 expression \( (P < 0.01) \), and RANK expression \( (P < 0.01) \) with breast cancer bone metastasis. Moreover, the authors analyzed the markers association with clinicopathological factors as provided in Table 5. CXCR4 and RANK were only significantly associated with the stage of breast cancer.

**Table 1: Characteristics of subjects.**

|                     | BM (n =29 ) | NBM (n =29 ) |
|---------------------|------------|-------------|
| Age (year)*         | 50(34-84)  | 50 (26-86)  |
| Menopause           |            |             |
| Yes                 | 15         | 15          |
| No                  | 14         | 14          |
| Stage               |            |             |
| Late (IV)           | 29         | 8           |
| Early (UII)         | 0          | 21          |
| Grade               |            |             |
| High(2, 3)          | 29         | 27          |
| Low (1)             | 0          | 2           |
| Tumor type          |            |             |
| NST                 | 19         | 17          |
| Others              | 10         | 12          |
| Lymph node involvement |        |             |
| Yes                 | 21         | 13          |
| No                  | 8          | 16          |
| ER/PR               |            |             |
| Positive            | 25         | 24          |
| Negative            | 4          | 5           |
| HER-2 amplification |            |             |
| Positive            | 18         | 14          |
| Negative            | 11         | 15          |
| CXCR4               |            |             |
| High                | 28         | 5           |
| Low                 | 1          | 24          |
| RANK                |            |             |
| High                | 28         | 7           |
| Low                 | 1          | 22          |

* median (minimum–maximum)

**Discussion**

In the BM group of this study, we found that CXCR4 was highly expressed in 28 (96.6%) subjects and lowly expressed in 1 (3.4%) patient. RANK was highly expressed in 28 (96.6%) subjects and lowly expressed in 1 (3.4%) patient.
subjects and lowly expressed in 1 (3.4%) patient. However, in the NBM group, CXCR4 was highly expressed in five (17.2%) subjects and lowly expressed in 24 (82.8%) subjects. RANK was highly expressed in seven (24.1%) subjects and lowly expressed in 22 (75.9%) subjects. CXCR4 and RANK combination was significantly associated with bone metastasis in breast cancer patients (P < 0.001). In this study, CXCR4 has a 97% sensitivity and an 83% specificity, RANK has 97% sensitivity and 76% specificity. Moreover, combined CXCR4 and RANK has 100% sensitivity and 66% specificity as a predictor for bone metastasis. This finding suits Ibrahim, et al. study which stated that combined CXCR4 and RANK expression could be a good predicting factor in breast cancer bone metastasis [10]. For comparison, other previous studies have also proposed other combinations of markers. Washam, et al. reported that the combination of 12-48aa peptide fragment of parathyroid hormone–related protein (PThrp(12-48)) and N-Telopeptide of type I collagen (NTx) resulted in 86% sensitivity and 95% specificity for the breast cancer bone metastasis detection [14]. Besides, Fujita et al. proposed the use of Sialyl Lewis X-1 (CSLEX-1) with Cancer Antigen 15-3 (CA 15-3) which resulted in 45% sensitivity and 95% specificity for detection of breast cancer metastasis, including 34.8% of the positive predictive value on the breast cancer bone metastasis [15].

In this study, there was only a significant association of CXCR4 and RANK combination with the breast cancer stage (P < 0.01). A previous study by Shim, et al. reported that high CXCR4 expression was significantly associated with higher histologic grade (P = 0.007), younger age (P = 0.008), and lower pathologic stage (P = 0.045) [16]. Besides, RANK expression was only significantly associated with operation type in a previous study by Park, et al. [17].

The pathogenesis of bone metastasis in breast cancer depends on the “vicious cycle”, which describes as the bidirectional tight interaction among breast cancer cells and stromal cells. This regulates the bone niche leading to continuous bone resorption process. An important pathway in the progressivity of breast cancer bone metastasis is RANK-RANKL- Osteoprotegerin (OPG) cascade [3]. These molecules are active in primary cancer cells including in their bone metastasis of breast, hepatocellular, and prostate carcinoma [18].

RANK is a surface receptor commonly found on mature osteoclasts and their progenitors [19]. It induces osteoclastogenesis and controls calcium metabolism. RANKL is a polypeptide which found on the surface of osteoblast and bone stromal cells [10]. It binds to RANK on preosteoclast and mature osteoclast. Signaling through RANK would activate transcription factors, which leads to the differentiation of osteoclast progenitors and limits apoptosis of mature osteoclast [20]. On the other hand, OPG (Osteoprotegerin) prevents the RANK-RANKL interaction on the osteoclast cell membrane [21]. If OPG binds to RANKL, osteoclastogenesis will be inhibited, resulting in bone resorption cessation [21]. However, the RANKL–RANK axis promotes the activation, proliferation, and survival of osteoclast. This stimulates tumorigenesis and metastasis in the bone. Studies reported that breast cancer cell expresses RANK protein on their surface, while RANK acts as a chemotactic factor of cancer cells [19,20]. A high amount of RANK within bone microenvironment may stimulate the migration of RANK expressing tumor cells to the bone. In a research by Ibrahim, et al. the positivity of RANK in the primary tumor was always associated with bone relapse [10]. However, 96.6% (28 of 29) of RANK positive subjects had bone metastasis in our study. This might happened because there were 62.1% subjects with HER-2 amplification in the BM group which leads to bigger tendency for visceral metastasis.

### Table 2: Association between CXCR4 and RANK toward breast cancer BM.

|   | BM | OR (95%CI) | P-value |
|---|---|---|---|
| CXCR4 High | 28 | 5 | 134.4 | <0.01* |
| Low | 1 | 24 | (14.7 -1231.5) |   |
| RANK High | 28 | 7 | 88.0 | <0.01* |
| Low | 1 | 22 | (10.1 – 769.5) |   |
| CXCR4+RANK High | 29 | 10 | ** | <0.01 |
| Low | 0 | 19 |   |   |

*OR: Odd Ratio *can’t be defined, one of the comparison had 0 value

### Table 3: Diagnosis accuracy of CXCR4 expression in breast cancer BM.

| Value | CXCR4 | RANK | CXCR4+RANK |
|---|---|---|---|
| Sensitivity | 97% | 97% | 100% |
| Specificity | 83% | 76% | 66% |
| Positive predictive value | 85% | 80% | 74% |
| Negative predictive value | 96% | 96% | 100% |

### Table 4: Association between clinopathological features with breast cancer BM.

| Stage | BM | NBM | P-value |
|---|---|---|---|
| Late (IV) | 29 | 0 | 21 | <0.01* |
| Early (I,II,III) | 0 | 13 | 16 |   |
| Grade | High (2,3) | 29 | 0 | 27 | 2 | 1.00 |
| Low (1) | 0 | 17 | 12 |   |
| Tumor type | NST | 19 | 10 | 17 | 12 | 0.59 |
| Others | 0 | 13 | 16 |   |
| Lymph node | Positive | 21 | 8 | 13 | 16 | 0.03 |
| Negative | 0 | 13 | 16 |   |
| ER/PR | Positive | 25 | 4 | 24 | 5 | 1.00 |
| Negative | 0 | 13 | 16 |   |
| HER-2 | Positive | 18 | 11 | 14 | 15 | 0.29 |
| Negative | 0 | 13 | 16 |   |
| Menopause | yes | 15 | 14 | 15 | 14 | 1.00 |
| no | 0 | 13 | 16 |   |
| CXCR4 | High | 28 | 1 | 5 | 24 | <0.01 |
| Low | 0 | 13 | 16 |   |
| RANK | High | 28 | 1 | 7 | 22 | <0.01 |

*Chi Square | Fisher Exact
One of the essential components of bone metastases is the chemotaxis of circulating tumor cells and the stromal cells within the bone environment. CXCR4 is the chemokine receptor used by circulating leukocytes and stem cells for homing to the bone marrow, where an excessive amount of their corresponding chemokine; Stromal Cell-Derived Factor-1 (SDF-1) is present [22,23]. The overexpression of CXCR4 was found in around 30% of primary breast cancer cells, which is proved to mediate cancer cells migrating to target organs, especially where SDF-1α is abundant such as bone [23].

A recent study noted the CXCR4 expression in primary breast cancer was significantly associated with the development of bone metastases [10,24]. Besides, RANK is highly expressed in primary breast cancer [25]. High expression of RANK in breast cancer stimulates migration to the bone which has a high expression of RANKL. Researchers found that predictive accuracy can be further increased with RANK expression [10]. Because both of these markers act in the early cascade of bone metastasis, we hope that these combinations might produce predictive factors with high sensitivity and specificity. In this study, we did not observe OPG because OPG is likely to increase the survival of breast cancer cells that metastasize to the bone environment [26]. The authors also didn’t observe RANKL because RANKL presents more abundantly in bone marrow environment [26]. The authors also didn’t observe RANKL because RANKL presents more abundantly in bone marrow environment [26].

Conclusions

In conclusion, a combination of CXCR4 high expression and RANK high expression can act as a predictor for breast cancer bone metastasis. Cancer staging plays an important role in determining CXCR4 and RANK expressions in breast cancer bone metastasis. Therefore, CXCR4 and RANK combination can be used as a screening method to predict bone metastasis in early-stage breast cancer in the future.

Acknowledgements

The authors would like to thank dr. Kevin Varian Marcevianto who assists the publication process of this research.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal Clinicians 68: 394-424. Link: https://bit.ly/3aDoZBvm
2. Anwar SL, Raharjo CA, Herviastuti R, Dwianingsih EK, Setyoheriyanto D, et al. (2019) Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: A hospital-based study. BMC Women’s Health 19: 1-8. Link: https://bit.ly/2MAixSp
3. Sejdinaj F, Zhang H (2017) Bone Microenvironment and Role of Rank-Rankl-Opg in Breast Cancer Metastasis in Bone. J Cancer Prev Curr Res 7: 00234. Link: https://bit.ly/3rwNSaP
4. Wong M, Pavlakis N (2011) Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Medical Press) 3: 35–60. Link: https://bit.ly/2YS8o9P
5. Schulman KL, Kohles J (2007) Economic burden of metastatic bone disease in the U.S. Cancer 109: 2334-2342. Link: https://bit.ly/3fBu3Rw
6. Bohn OL, Nasir I, Brufsky A, Tseng GC, Bhargava R, et al. (2009) Biomarker profile in breast carcinomas presenting with bone metastasis. International Journal of Clinical and Experimental Pathology 3: 139-146. Link: https://bit.ly/3cR6rXG

**Table 5**: Association between clinicopathological features with CXCR4 and RANK expression.

| Variable       | CXCR4 | RANK | CXCR4+RANK |
|----------------|-------|------|------------|
|                | High  | Low  | High       | Low  | High | Low  |                | P-value CXCR4 | P-value RANK | P-value CXCR4+RANK |
| Stage          |       |      |            |      |      |      |                | <0.01*        | <0.01*        | <0.01*                  |
| Late (IV)      | 29    | 8    | 31          | 6    | 33   | 4    |                |               |               |                           |
| Early (I,II)   | 4     | 17   | 4           | 17   | 6    | 15   |                |               |               |                           |
| Grade          |       |      |            |      |      |      |                | 1.00*         | 1.00*         | 1.00*                  |
| High (2,3)     | 32    | 24   | 34          | 22   | 38   | 18   |                |               |               |                           |
| Low (1)        | 1     | 1    | 1           | 1    | 1    | 1    |                |               |               |                           |
| Tumor type     |       |      |            |      |      |      |                | 0.78a         | 0.88a         | 0.65a                  |
| NST            | 21    | 15   | 22          | 14   | 25   | 11   |                |               |               |                           |
| Others         | 12    | 10   | 13          | 9    | 14   | 8    |                |               |               |                           |
| ER/PR          |       |      |            |      |      |      |                | 1.00a         | 0.18a         | 0.23a                  |
| Positive       | 28    | 21   | 23          | 11   | 25   | 9    |                |               |               |                           |
| Negative       | 5     | 4    | 12          | 12   | 14   | 10   |                |               |               |                           |
| HER-2          |       |      |            |      |      |      |                | 0.67a         | 1.00a         | 1.00a                  |
| Positive       | 19    | 13   | 30          | 19   | 33   | 16   |                |               |               |                           |
| Negative       | 14    | 12   | 5           | 4    | 6    | 3    |                |               |               |                           |
| Lymph node     |       |      |            |      |      |      |                | 0.15a         | 0.36a         | 0.786                  |
| Positive       | 22    | 12   | 21          | 11   | 22   | 10   |                |               |               |                           |
| Negative       | 11    | 13   | 14          | 22   | 17   | 9    |                |               |               |                           |
| Menopause      |       |      |            |      |      |      |                | 0.97a         | 0.96a         | 0.51a                  |
| yes            | 17    | 13   | 18          | 12   | 19   | 11   |                |               |               |                           |
| no             | 16    | 12   | 17          | 11   | 20   | 8    |                |               |               |                           |

*Chi Square
**Fisher Exact
7. Kruger TE, Miller AH, Godwin AK, Wang J (2014) Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol 89: 330-341. Link: https://bit.ly/3FyYkK

8. Schneider JG, Amend SR, Weilbaecher KN (2011) Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions. Bone 48: 54-65. Link: https://bit.ly/3u6Pbw

9. D’Oronzo S, Brown J, Coleman R (2017) The role of biomarkers in the management of bone-homing malignancies. Journal of Bone Oncology 9: 1–9. Link: https://bit.ly/39YBqDF

10. Wu X, Li F, Tang L, Liang C, Lu A, et al. (2020) RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. In Frontiers in Cell and Developmental Biology 8: 76. Link: https://bit.ly/3K4OuT

11. Wu X, Li F, Tang L, Liang C, Lu A, et al. (2020) RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. In Frontiers in Cell and Developmental Biology 8: 76. Link: https://bit.ly/3K4OuT

12. Sun Y, Mao X, Fan C, Liu C, Guo A, et al. (2014) CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumour Biology 35: 7765-7773. Link: https://bit.ly/365J25p

13. Li X, Liu Y, Wu B, Dong Z, Wang Y, et al. (2014) Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncol Rep 32: 2605-2611. Link: https://bit.ly/2MjI6eX

14. Washam CL, Byrum SD, Leitzel K, Ali SM, Tackett AJ, et al. (2013) Identification of PTHrP(12-48) as a Plasma Biomarker Associated with Breast Cancer Bone Metastasis. Cancer Epidemiol Biomarkers Prev 22: 972LP-983. Link: https://bit.ly/2Lxqqeo

15. Fujita T, Murayama K, Hanamura T, Okada T, Ito T, et al. (2011) CSLEX (Sialyl Lewis X) is a useful tumor marker for monitoring of breast cancer patients. Jpn J Clin Oncol 41: 394-399. Link: https://bit.ly/3tySwXM

16. Shin B, Jin MS, Moon JH, Park IA, Ryu HS (2018) High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy. J Pathol Transl Med 52: 369–377. Link: https://bit.ly/39WczOy

17. Park HS, Lee A, Chae BJ, Bae JS, Song BJ, et al. (2014) Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol 110: 807-812. Link: https://bit.ly/3q16XII

18. Attieri B, Di Dato C, Martini C, Sciammarella C, Di Sano A, et al. (2019) Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers 11: 1332. Link: https://bit.ly/2Yy6c01

19. Azim HA, Kamal NS, Azim HA (2012) Bone metastasis in breast cancer: The story of RANK-Ligand. J Egypt Natl Canc Inst 24: 107–114. Link: https://bit.ly/39X5c2J

20. Infante M, Favi A, Cognetti F, Gorini S, Caprio M, et al. (2019) RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res 38: 12. Link: https://bit.ly/2LtcVMD

21. Sisay M, Mengistu G, Edessa D (2017) The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. Onco Targets Ther 10: 3801-3810. Link: https://bit.ly/3jU7ObU

22. Liu Y, Ji R, Li J, Gu Q, Zhao X, et al. (2010) Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. Journal of Experimental Clinical Cancer Research 29: 16. Link: https://bit.ly/3oYWRQz

23. Masuda T, Endo M, Yamamoto Y, Odagiri H, Kadomatsu T, et al. (2015) ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling. Scientific Reports 5. Link: https://bit.ly/3TiyTeu

24. Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W (2011) The role of CXCR4 in the prediction of bone metastases from breast cancer: A pilot study. Oncology 80: 225-231. Link: https://bit.ly/39X6PNT

25. Ney JT, Fehm T, Juhasz-Boess I, Solomayer EF (2012) RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis. Geburtshilfe Frauenheilkunde 72: 385-391. Link: https://bit.ly/3nNhVk

26. Goswami S, Sharma-Walia N (2016) Osteoprotegerin rich tumor microenvironment: implications in breast cancer. Oncotarget 7: 42777-42791. Link: https://bit.ly/2MXxwR